ATE216590T1 - Arzneimittelformulierungen für il-12 - Google Patents

Arzneimittelformulierungen für il-12

Info

Publication number
ATE216590T1
ATE216590T1 AT96905322T AT96905322T ATE216590T1 AT E216590 T1 ATE216590 T1 AT E216590T1 AT 96905322 T AT96905322 T AT 96905322T AT 96905322 T AT96905322 T AT 96905322T AT E216590 T1 ATE216590 T1 AT E216590T1
Authority
AT
Austria
Prior art keywords
drug formulations
formulations
administration
methods
storage
Prior art date
Application number
AT96905322T
Other languages
English (en)
Inventor
Nicholas W Warne
Thomas J Crowley
Tracy M Smith
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Inst filed Critical Genetics Inst
Application granted granted Critical
Publication of ATE216590T1 publication Critical patent/ATE216590T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96905322T 1995-02-06 1996-02-02 Arzneimittelformulierungen für il-12 ATE216590T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38406295A 1995-02-06 1995-02-06
PCT/US1996/001382 WO1996024369A1 (en) 1995-02-06 1996-02-02 Formulations for il-12

Publications (1)

Publication Number Publication Date
ATE216590T1 true ATE216590T1 (de) 2002-05-15

Family

ID=23515877

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96905322T ATE216590T1 (de) 1995-02-06 1996-02-02 Arzneimittelformulierungen für il-12

Country Status (7)

Country Link
US (1) US5744132A (de)
EP (1) EP0820299B1 (de)
JP (1) JP2000510813A (de)
AT (1) ATE216590T1 (de)
AU (1) AU695129B2 (de)
DE (1) DE69620877T2 (de)
WO (1) WO1996024369A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
JP3643034B2 (ja) * 1998-03-26 2005-04-27 シェーリング コーポレイション ＰＥＧ−インターフェロンα結合体の保護のための処方物
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US6080399A (en) * 1998-04-23 2000-06-27 Arch Development Corporation Vaccine adjuvants for immunotherapy of melanoma
JP4557098B2 (ja) * 1999-03-31 2010-10-06 味の素株式会社 安定な６−アミジノ−２−ナフチル４−グアニジノベンゾエート酸付加塩製剤ならびにその製造方法
NZ516664A (en) * 1999-07-15 2003-06-30 Inst Genetics Llc Formulations and compositions for interleukin-11
EP3184637A1 (de) 1999-09-09 2017-06-28 Merck Sharp & Dohme Corp. Komplexe aus säugetier-interleukin-12 p40 und interleukin b30, antikörper, verwendung in pharmazeutischen zusammensetzungen
US7090847B1 (en) * 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
CN1245216C (zh) * 1999-10-04 2006-03-15 希龙公司 稳定化的含多肽的液体药物组合物
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
WO2002072144A1 (en) * 2001-03-12 2002-09-19 Institute Of Gene And Brain Science Remedies for nerve damages
US20030119734A1 (en) 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
US20030129161A1 (en) * 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
ES2392073T3 (es) * 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20040265943A1 (en) * 2002-09-23 2004-12-30 Aventis Pharma S.A. Method for quantitatively determining specific groups constituting heparins or low molecular weight heparins
DK1599222T3 (da) 2003-01-08 2009-04-27 Novartis Vaccines & Diagnostic Stabiliserede vandige pr parater omfattende v vsfaktorvej-inhibitor (TFPI) eller v vsfaktorvej-inhibitorvariant
MXPA05008156A (es) * 2003-02-01 2005-09-30 Neuralab Ltd Inmunizacion activa para generar anticuerpos para beta-a soluble.
PE20050627A1 (es) * 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
WO2004105790A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
US7939058B2 (en) * 2003-07-03 2011-05-10 University Of Southern California Uses of IL-12 in hematopoiesis
PT1687019T (pt) 2003-11-20 2018-02-26 Novo Nordisk As Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
DE602005022895D1 (de) 2004-08-12 2010-09-23 Schering Corp Stabile pegylierte interferon-formulierung
AU2005277357B2 (en) * 2004-08-17 2011-08-04 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
EP2494983B1 (de) 2004-11-12 2019-04-24 Novo Nordisk A/S Stabile formulierung von glp-1
ES2396555T3 (es) * 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
PE20061329A1 (es) * 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
US20060257396A1 (en) * 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
KR20070107079A (ko) * 2005-01-28 2007-11-06 와이어쓰 안정화된 액체 폴리펩타이드 제형
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
AU2011265555B2 (en) * 2006-04-21 2016-03-10 Amgen Inc. Lyophilized therapeutic peptibody formulations
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
PL2097068T3 (pl) * 2006-11-24 2013-12-31 Cadila Healthcare Ltd Preparaty koniugatów PEG-interferon alfa
MX2009008692A (es) * 2007-02-16 2009-08-21 Wyeth Corp Uso de sacarosa para suprimir la agregacion de proteina inducida por manitol.
CN101605532A (zh) * 2007-02-16 2009-12-16 惠氏公司 含有山梨糖醇的蛋白质调配物
EP2146746A4 (de) * 2007-04-18 2011-03-23 Janssen Alzheimer Immunotherap Vorbeugung und behandlung von zerebraler amyloid-angiopathy
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US8921315B1 (en) 2008-04-24 2014-12-30 Neumedicines, Inc. Method of increasing survival of a human subject having exposure to an acute exposure to non-therapeutic whole body ionization by administering a therapeutically effective dose of IL-12
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CA2800348C (en) 2010-05-18 2020-07-21 Lena A. Basile Il-12 formulations for enhancing hematopoiesis
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
US9925246B2 (en) 2011-06-13 2018-03-27 Neumedicines, Inc. Mitigation of cutaneous injury with IL-12
US20140178335A1 (en) 2011-07-27 2014-06-26 Neumedicines, Inc. Use of il-12 to generate endogenous erythropoietin
HRP20230065T1 (hr) 2011-10-28 2023-03-03 Prothena Biosciences Limited Humanizirana protutijela koja prepoznaju alfa-sinuklein
US9616106B2 (en) * 2012-01-18 2017-04-11 Neumedicines, Inc. IL-12 for radiation protection and radiation-induced toxicity mitigation
SG11201404321YA (en) 2012-01-27 2014-08-28 Neotope Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
SG10202103879YA (en) 2015-02-04 2021-05-28 Boehringer Ingelheim Int Methods of treating inflammatory diseases
HUE066356T2 (hu) 2017-08-24 2024-07-28 Novo Nordisk As GLP-1 készítmények és alkalmazásaik
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
TW202123965A (zh) * 2019-09-09 2021-07-01 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
PE20221575A1 (es) 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3262575D1 (en) * 1981-12-23 1985-04-18 Schering Corp Stabilised interferon formulations and their preparation
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
GR871067B (en) * 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
US5215743A (en) * 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
ATE140483T1 (de) * 1988-11-10 1996-08-15 Genetics Inst Natürlicher killerzellen-stimulationsfaktor
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
DK0790255T3 (da) * 1989-12-22 2007-11-26 Hoffmann La Roche Monoklonale antistoffer som er rettet mod den cytotoksiske lymfocytmodningsfaktor
IT1254359B (it) * 1992-05-11 1995-09-14 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti il-6
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
JPH06247870A (ja) * 1993-02-23 1994-09-06 Ajinomoto Co Inc インターロイキン−６を含有する医薬製剤
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
US5573764A (en) * 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease

Also Published As

Publication number Publication date
WO1996024369A1 (en) 1996-08-15
EP0820299A1 (de) 1998-01-28
EP0820299B1 (de) 2002-04-24
DE69620877T2 (de) 2002-12-12
AU695129B2 (en) 1998-08-06
JP2000510813A (ja) 2000-08-22
DE69620877D1 (de) 2002-05-29
AU4911996A (en) 1996-08-27
MX9705959A (es) 1997-11-29
US5744132A (en) 1998-04-28

Similar Documents

Publication Publication Date Title
DE69620877D1 (de) Arzneimittelformulierungen für il-12
DK0758248T3 (da) Formuleringer til faktor IX
ATE270557T1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
DK1093819T3 (da) Forbindelse og præparat til tilförsel af aktive midler
WO2001005355A3 (en) Formulations for il-11
NO990789D0 (no) Cytotoksisk aminosukker og beslektede sukker-derivater av indolopyrrolokarbazoler
ATE554750T1 (de) Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
DK0548114T5 (da) Mometason-furoat-monohydrat, fremgangsmåde til fremtilling deraf og farmaceutiske præparater indeholdende dette
DE60038183D1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
FI964681A0 (fi) Ihmisperäiset Lactobacillus-kannat, niitä sisältävät valmisteet ja niiden käytöt
MA26458A1 (fr) Nouveaux derives cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent.
DK0994710T3 (da) Farmaceutiske præparater til oral indgivelse omfattende en benzhydrylpiperazin og en cyclodextrin
RU95108590A (ru) Производные имидазола
SE9201628D0 (sv) Pharmaceutical composition
DK0902789T3 (da) Androstenderivater
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
DE69102704D1 (de) Orales, melatonin enthaltendes arzneimittel.
RU94038042A (ru) Производные гексагидроазепинов, фармацевтическая композиция на их основе и антипсихотропный агент
IT1270618B (it) Proteine ad attivita' antitumorale
ATE28188T1 (de) Antikonvulsive mittel.
ATE227122T1 (de) Stabilisierte tablettenformulierung
MX9803791A (es) Intermediarios novedosos y su uso para preparar bisindolilmaleimidas n,n'-puenteadas.
ES2162986T3 (es) Derivados de mercapto-alcanoil-dipeptidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
DK630088A (da) Azelastinembonat, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater med indhold af denne forbindelse som aktivt middel